Announcement of the resolution of the third session of the 10th board of directors
Release time:
2020-08-05
证券代码:600668 证券简称:尖峰集团 编号:临2018-004
债券简称:13尖峰01 债券代码:122227
债券简称:13尖峰02 债券代码:122344
浙江尖峰集团股份有限公司
十届3次董事会决议公告
本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏,并对其内容的真实性、准确性和完整性承担个别及连带责任。
一、董事会会议召开情况
(一)本次董事会会议的召集、召开符合有关法律、法规及公司《章程》的相关规定。
(二)2018年4月9日,公司以传真、电子邮件及专人送达的方式发出了本次董事会会议通知。
(三)2018年4月20日,本次董事会会议在浙江省金华市尖峰大厦三楼会议室以现场表决方式召开。
(四)本次董事会会议应出席的董事9人,实际出席会议的董事9人,会议有效表决票数9票。
(五)本次董事会由董事长蒋晓萌主持,公司监事和高级管理人员列席会议。
二、董事会会议审议情况
1、通过了2017年度总经理业务报告
董事会审议并通过了该报告。
表决结果:同意9票、反对0票、弃权0票。
2、通过了2017年度财务决算报告
董事会审议并通过了该报告。
表决结果:同意9票、反对0票、弃权0票。
本报告需提交股东大会审议
3、通过了2017年度利润分配预案
经天健会计师事务所(特殊普通合伙)审计,2017年度公司合并报表归属于母公司股东的净利润为348,494,304.06元;母公司会计报表净利润194,066,681.11元。按母公司的本期净利润194,066,681.11元为基数,提取10%法定公积金19,406,668.11 元,加年初未分配利润570,339,566.43元,减去2016年度现金分红86,020,957.00元,本年度可供分配利润为658,978,622.43元。
公司2017年度拟进行现金分配,以2017年末股本344,083,828股为基数,每10股派发现金红利1.0元(含税),向股权登记日登记在册的全体股东派发现金股利总额为34,408,382.8 元(含税)。
2017年度不进行公积金转增股本。
董事会说明:
(1)现金分红政策执行情况
《公司章程》规定:公司最近三年以现金方式累计分配的利润不少于最近三年实现的年均可分配利润的百分之三十。
从2011年以来,公司连续进行了现金分红,已累计实施现金分红38881.47万元,最近三年现金分红情况如下(2017年度暂按上述预案计算,单位:万元):
|
分红年度 |
现金分红数额 |
当年合并归母公司净利润 |
现金分红占当年合并归母公司净利润比例 |
|
2015年 |
6193.51 |
20089.94 |
30.83% |
|
2016年 |
8602.10 |
28522.95 |
30.16% |
|
2017年 |
3440.84 |
34849.43 |
9.87% |
|
|
最近三年以现金方式累计分配 |
最近三年实现的年均可分配利润 |
最近三年以现金方式累计分配的利润占最近三年实现的年均可分配利润的比例 |
|
|
18236.44 |
27820.77 |
65.55% |
公司最近三年以现金方式累计分配的利润占最近三年实现的年均可分配利润的比例为65.55%,符合公司《公司章程》规定的现金分红政策。
(2)公司的发展情况
目前,公司正处于发展的关键阶段,2018年公司将加快推进上海北卡项目,其子公司安徽新北卡化学有限公司需进行技术改造,建设“年产350吨医药中间体及900吨农药原药项目”;尖峰药业“DPT”项目进入一期临床试验,尖峰药业及其子公司浙江尔婴(原金得尔)、尖峰亦恩将进一步加大产品研发和引进力度;2018年度公司还将继续投入并完成尖峰国贸“新建仓库(电商物流园)项目”;上述业务的开展需要较大的资金支持。
(3)考虑到2018年公司在技改、新产品开发等方面的投入较大,为了保持公司的稳健经营,支持公司的长远发展,兼顾股东的短期和长期利益,董事会通过了上述2017年度利润分配预案。
(4)公司将召开2017年度业绩及现金分红说明会,就公司2017年度业绩及现金分红事项与投资者进行沟通和交流,及时答复投资者关心的问题。
(5)公司在召开股东大会审议上述2017年度利润分配预案时,将为投资者提供网络投票便利条件,同时按照参与表决的A股股东的持股比例分段披露表决结果。
独立董事意见:
(1)同意公司以2017年末股本344,083,828股为基数,每10股派发现金红利1.0元(含税),向股权登记日登记在册的全体股东派发现金股利总额为34,408,382.8元(含税),2017年度不进行公积金转增股本。
(2)该利润分配预案是根据公司2017年度实际经营成果及财务状况,结合公司未来业务发展的实际需要而制定。留存未分配利润主要用于满足公司公司发展的资金需求,有利于公司的持续健康发展,不存在损害股东特别是中小股东权益的情况。我们认为其符合《公司章程》对于利润分配的相关规定,符合公司的实际经营状况。
(3)公司董事会审议通过了上述利润分配预案。我们认为本次会议的召集、召开及审议表决程序符合相关法律、法规及《公司章程》的规定,合法有效;并同意将该预案提交公司2017年年度股东大会审议。
表决结果:同意9票、反对0票、弃权0票。
该预案将提交股东大会审议。
4、通过了聘请公司2018年度审计机构的议案
董事会审议并通过了该议案,同意聘请天健会计师事务所(特殊普通合伙)为公司2018年度财务及内部控制审计机构。
表决结果:同意9票、反对0票、弃权0票。
本议案需提交股东大会审议。
5、通过了2017年年度报告及其摘要
董事会审议并通过了该报告。
表决结果:同意9票、反对0票、弃权0票。
本议案需提交股东大会审议。2017年度报告全文及摘要详见上海证券交易所网站(www.sse.com.cn)。
6、通过了关于对控股子公司提供担保的议案
经审议与表决,董事会通过了该议案。
表决结果:同意9票、反对0票、弃权0票。
本议案需提交股东大会审议。
详见《对控股子公司提供担保的公告》(临2018-008)。
7、关于授权董事长利用自有资金进行委托理财的议案
经审议与表决,董事会通过了该议案。
表决结果:同意9票、反对0票、弃权0票。
详见《关于授权董事长利用自有资金进行委托理财的公告》(临2018-007)。
8、关于子公司日常关联交易的议案
董事会审议并通过了该议案。
表决结果:同意7票、反对0票、弃权0票。关联董事蒋晓萌、杜自弘回避了该议案的表决。
详见《关于子公司日常关联交易公告》(临2018-006)。
9、通过了关于召开2017年度股东大会的议案
经审议与表决,董事会通过了该议案。
表决结果:同意9票、反对0票、弃权0票。
详见《关于召开2017年度股东大会的通知》(临2018-010)。
10、通过了2017年度内部控制评价报告
董事会审议并通过了该报告。
表决结果:同意9票、反对0票、弃权0票。
内部控制评价报告详见上海证券交易所网站(www.sse.com.cn)。
11、通过了关于新北卡化学技术改造项目的议案
董事会审议并通过了该议案。同意子公司安徽新北卡化学有限公司投资16274.25万元,其中:固定资产投资为13274.25万元,流动资金3000万元。建设“年产350吨医药中间体及900吨农药原药项目”。
表决结果:同意9票、反对0票、弃权0票。
12、通过了2017年度《中长期激励基金计提方案》
董事会审议并通过了该议案。根据《中长期激励管理办法》的规定,2017年度可提取中长期激励基金为13836266.94元。
表决结果:同意9票、反对0票、弃权0票。
13、通过了董事会审计委员会2017年度履职报告
董事会审议并通过了该报告。
表决结果:同意9票、反对0票、弃权0票。
14、通过了独立董事2017年度述职报告
董事会审议并通过了该报告。
表决结果:同意9票、反对0票、弃权0票
独立董事将向股东大会报告。
15、通过了2017年度董事会工作报告
表决结果:同意9票、反对0票、弃权0票。
该报告将提交股东大会审议。
公司独立董事的独立意见:
公司独立董事对上述4、6、7、8、12五项决议发表了独立意见,认为:该决议的形成符合《公司法》、公司《章程》等有关规定,没有损害中小股东的利益。
三、上网公告附件
公司第十届独立董事对上述相关事项的独立董事意见。
特此公告
浙江尖峰集团股份有限公司董事会
二〇一八年四月二十四日
More information
Jingmai Airport Test Flight Successfully Runway Cement Spike Manufacturing
On April 7, a Boeing 737-700 aircraft of China Eastern Airlines Yunnan took off from Kunming. After completing two flight test subjects, it landed safely at Lancang Jingmai Airport. This not only marked the basic completion of the airport flight area, The official start of the test flight also marked that the "Peak" brand airport runway cement passed the first "final exam". Lancang Jingmai Airport is a major project with milestone significance in the history of Pu'er transportation construction. Since then, an air corridor connecting southwest Yunnan and Southeast Asia has been added between Kunming and Pu'er, which will greatly promote the development and utilization of tourism resources in Lancang, Menglian and Ximeng "Pu'er Green Triangle" area, and promote the sustainable development of local economy and society; it is of great significance to strengthen the city's national defense construction, maintain border stability, promote national unity, improve emergency rescue capabilities, and promote Pu'er's integration into the country's "Belt and Road" construction. Since the start of the construction of the airport, Yunnan Jianfeng has been paying close attention to it, organizing technical research and repeated tests, and finally produced high-quality airport runway special cement, and with excellent product quality, superior product performance and high-quality service, it has become a runway for Lancang Airport. Cement manufacturer. This not only fills the gap of "peak" airport special cement, but also is of great significance to promote the "peak" brand and improve the market influence of enterprises. It is understood that Jingmai Airport is initially confirmed to be officially opened to traffic at the end of May. (Li Liangping)
2020
07-31
Jianfeng Pharmaceutical Artificial Niuhuang Project Starts
News from this newspaper Jianfeng Pharmaceutical artificial bezoar technical transformation project recently started construction in Qiubin Factory. Artificial bezoar has the effect of clearing away heat and detoxification, resolving phlegm, and is commonly used in Chinese and Western medicines such as colds, clearing away heat and detoxification. As the vast majority of artificial bezoar-related preparations are national essential drugs, with the further implementation of the medical reform policy, the downstream industry of artificial bezoar will enter a new round of business cycle. Jianfeng Pharmaceutical has many years of experience in artificial bezoar production. The technological transformation project will use the existing workshop structure, public works and operators of Qiubin Factory to achieve an annual production capacity of 100 tons of artificial bezoar by adding production equipment such as double cone rotary vacuum drying, horizontal ball mill pulverizer unit, hopper and hoist, closed screening system, and upgrading some public systems. According to the project implementation plan, the project will complete the civil engineering in May. Complete the commissioning, testing and verification of equipment and facilities in July, with trial production conditions; Strive to complete the on-site inspection of GMP certification before the end of December. At present, the factory buildings in Qiubin are vacated and the site is cleaned up. It is understood that the production of natural bezoar is very small, the price is extremely high, and the market rarely provides it. As a biochemical API, artificial bezoar has fewer manufacturers. In the past, due to relatively loose supervision, the testing methods of raw materials and finished products are relatively simple, the quality control indicators are not perfect, and the quality of products on the market is uneven. It is imperative to improve the quality standards. To this end, the State Food and Drug Administration issued the "Biochemical Drug GMP Quality Management Practice (Draft for Comment)" at the end of 2016, which was implemented in March 2017. spike medicine
2020
07-31
Recently, Jianfeng Health has been awarded a number of plaques and certificates by the Department of Science and Technology of Zhejiang Province, the people's Government of Jinhua City, and the Science and Technology Bureau of Jinhua City. They are "Zhejiang Science and Technology small and medium-sized Enterprises", "Jinhua High-tech Enterprises", "Jinhua Agricultural Science and Technology Enterprises", "Jinhua Agricultural Science and Technology Research and Development Center" and so on. According to the relevant requirements, Zhejiang science and technology-based small and medium-sized enterprises must be small and medium-sized enterprises with independent intellectual property rights, proprietary technology or advanced knowledge, engaged in the research, development, production, sales and service of high-tech and its products, and the proportion of enterprises engaged in scientific and technological research and development personnel accounting for no less than 10% of the total number of employees in that year. Since its establishment, Jianfeng Health has attached great importance to the training of scientific and technological personnel, paid attention to the application of its own intellectual property rights, paid attention to product research and development and the protection of intellectual property rights, promoted the application of intellectual property rights, and encouraged employees to invent and create. By the end of 2016, a total of 8 invention patents and 5 appearance patents had been applied, and 1 invention patent and 5 appearance patents had been obtained. High-tech enterprises in Jinhua City must meet the requirements of the ''High-tech Fields Supported by the State, ''and continue to carry out research and development and technological achievements transformation. Their main products (services) have independent intellectual property rights (authorized, registered or accepted). There are certain requirements for the proportion of R & D personnel, the proportion of R & D funds and the income of high-tech products. The acquisition of high-tech enterprises in Jinhua City has laid the foundation for the further declaration of national high-tech enterprises in the future. In the identification of agricultural science and technology enterprises in Jinhua City, the field of peak health technology belongs to the deep processing technology and equipment of agricultural products, Chinese herbal pieces and plant extracts.
2020
07-31
Jingmai Airport Test Flight Successfully Runway Cement Spike Manufacturing
On April 7, a Boeing 737-700 aircraft of China Eastern Airlines Yunnan took off from Kunming. After completing two flight test subjects, it landed safely at Lancang Jingmai Airport. This not only marked the basic completion of the airport flight area, The official start of the test flight also marked that the "Peak" brand airport runway cement passed the first "final exam". Lancang Jingmai Airport is a major project with milestone significance in the history of Pu'er transportation construction. Since then, an air corridor connecting southwest Yunnan and Southeast Asia has been added between Kunming and Pu'er, which will greatly promote the development and utilization of tourism resources in Lancang, Menglian and Ximeng "Pu'er Green Triangle" area, and promote the sustainable development of local economy and society; it is of great significance to strengthen the city's national defense construction, maintain border stability, promote national unity, improve emergency rescue capabilities, and promote Pu'er's integration into the country's "Belt and Road" construction. Since the start of the construction of the airport, Yunnan Jianfeng has been paying close attention to it, organizing technical research and repeated tests, and finally produced high-quality airport runway special cement, and with excellent product quality, superior product performance and high-quality service, it has become a runway for Lancang Airport. Cement manufacturer. This not only fills the gap of "peak" airport special cement, but also is of great significance to promote the "peak" brand and improve the market influence of enterprises. It is understood that Jingmai Airport is initially confirmed to be officially opened to traffic at the end of May. (Li Liangping)
2020
07-30
Peak Pharmaceutical was rated as a national intellectual property advantage enterprises
The score ranked first among Jinhua participating enterprises. A few days ago, Peak Pharmaceutical Company was rated as a national intellectual property advantage enterprise. The selection of national intellectual property advantage enterprises is organized by the State Intellectual Property Office. The purpose is to accelerate the formation of a group of Chinese intellectual property leading enterprises with independent intellectual property rights, well-known brands and international competitive advantages, and achieve the development goal of strong intellectual property enterprises. Since Jianfeng Pharmaceutical introduced the GB-T29490-2013 "Enterprise Intellectual Property Management Standard" in 2013, it has been rated as a patent demonstration enterprise in Zhejiang Province in 2013. In 2014, the "Jianfeng" trademark obtained a famous trademark in Zhejiang Province, and the first edition of the "Intellectual Property Manual" was compiled and implemented in 2015. In 2016, it passed the third-party certification of the GB-T29490-2013 "Enterprise Intellectual Property Management Standard". The "Jianfeng" trademark was rated as a well-known trademark by the State Administration of China. In the application and selection of national knowledge by superior enterprises, 52 enterprises in Zhejiang Province won this honor, ranking second in the country in number; Jianfeng Pharmaceutical ranked first among Jinhua participating enterprises. (Zhang Mingyin)
2020
07-31
Group Party Committee to determine the annual work plan
The party Committee of the group company has determined its work ideas and work plan for 2017 a few days ago, and relevant work has been arranged below. In view of the current new political and economic situation and the task of enterprise transformation and development, the general requirements of the Party Committee of the Group Company for 2017 are: to thoroughly study and implement the spirit of the Sixth Plenary Session of the 18th CPC Central Committee and the series of important speeches by General Secretary Xi Jinping, the spirit of the Seventh Party Congress of Jinhua City, to closely revolve around the center of enterprise production, operation and reform and development, and to adhere to scientific development and cross-regional development as the first priority, in order to continue to carry out the study and education of "five stars striving for innovation" and "two learning and one doing", we should highlight the main line of comprehensively and strictly administering the party according to the rules, firmly establish the political consciousness, overall situation consciousness, core consciousness and alignment consciousness of the majority of Party members and cadres, strengthen and improve the party building work in enterprises in the spirit of reform, and strive to improve the scientific, standardized and institutionalized level of Party building work in enterprises, in order to promote the scientific development of the group company, leapfrog development and harmonious development, it provides a strong political, ideological and organizational guarantee. The working idea of the Party Committee of the Group Company in 2017 is to focus on "one center", adhere to "one concept", highlight "three key points" and do a good job in "three constructions". That is: centering on the "one center" of enterprise production, operation and reform and development, we should strive to strengthen the "one concept" of "the organic unity of the party's leadership and the improvement of corporate governance"; to "thoroughly implement the main responsibility of the party committee; continue to carry out the study and education of" two learning and one doing "; and improve the system of party building work" as the "three key points", and focus on "team building and team building
2020
07-31